Stereotaxis Publishes Clinical Results Using MAGiC Catheter in Journal of Interventional Cardiac Electrophysiology.
PorAinvest
martes, 1 de julio de 2025, 11:18 am ET1 min de lectura
STXS--
The prospective multi-center, single-arm study treated patients with various arrhythmias, including atrioventricular nodal reentrant tachycardia, Wolf-Parkinson-White syndrome, atrial fibrillation, atrial flutter, premature ventricular contractions, and ventricular tachycardia, in all four chambers of the heart. The initial analysis includes acute efficacy and safety for 67 patients, with patient enrollment ongoing and sustained efficacy assessments continuing for up to one year.
The study reported a 94% acute efficacy rate, which compares favorably to larger ablation registries using other catheters. Procedure time averaged 83 minutes skin-to-skin, and the procedure-related adverse event rate was 1.5%, reflecting known risks of RF ablation in high-risk patients and not caused by any catheter-related malfunction.
The study authors highlighted several notable aspects of the MAGiC catheter, including its improved stability, which does not require sheaths for support, steady catheter tip temperatures during ablation, low irrigation rates benefiting patients with poor cardiac and renal function, and the potential for more efficient and effective lesions.
Stereotaxis' MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to enhance treatment precision and control during cardiac ablation while maintaining the intrinsic safety advantage of a soft, flexible catheter. The company's robotic technologies are at the forefront of efforts to advance robotics in minimally-invasive endovascular surgeries, having already treated over 150,000 patients across the globe.
The publication can be found at [2], and a complete database of more than 500 scientific publications referencing Stereotaxis technology is available at www.RoboticEP.com/clinical-data/publications-database/.
References:
[1] https://finance.yahoo.com/news/first-clinical-results-magic-catheter-130000075.html
[2] https://link.springer.com/article/10.1007/s10840-025-02082-z
Stereotaxis has announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The study found a 94% acute efficacy rate and a 1.5% procedure-related adverse event rate. The catheter demonstrated good stability, low irrigation rates, and the potential for more efficient and effective lesions. The study's authors noted that these results compare favorably to larger ablation registries using other catheters.
Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology [1]. The study, titled "First In-Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter," is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis' MAGiC catheter.The prospective multi-center, single-arm study treated patients with various arrhythmias, including atrioventricular nodal reentrant tachycardia, Wolf-Parkinson-White syndrome, atrial fibrillation, atrial flutter, premature ventricular contractions, and ventricular tachycardia, in all four chambers of the heart. The initial analysis includes acute efficacy and safety for 67 patients, with patient enrollment ongoing and sustained efficacy assessments continuing for up to one year.
The study reported a 94% acute efficacy rate, which compares favorably to larger ablation registries using other catheters. Procedure time averaged 83 minutes skin-to-skin, and the procedure-related adverse event rate was 1.5%, reflecting known risks of RF ablation in high-risk patients and not caused by any catheter-related malfunction.
The study authors highlighted several notable aspects of the MAGiC catheter, including its improved stability, which does not require sheaths for support, steady catheter tip temperatures during ablation, low irrigation rates benefiting patients with poor cardiac and renal function, and the potential for more efficient and effective lesions.
Stereotaxis' MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to enhance treatment precision and control during cardiac ablation while maintaining the intrinsic safety advantage of a soft, flexible catheter. The company's robotic technologies are at the forefront of efforts to advance robotics in minimally-invasive endovascular surgeries, having already treated over 150,000 patients across the globe.
The publication can be found at [2], and a complete database of more than 500 scientific publications referencing Stereotaxis technology is available at www.RoboticEP.com/clinical-data/publications-database/.
References:
[1] https://finance.yahoo.com/news/first-clinical-results-magic-catheter-130000075.html
[2] https://link.springer.com/article/10.1007/s10840-025-02082-z

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios